Trial Profile
A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Olipudase alfa (Primary)
- Indications Niemann-Pick disease type B
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 22 Aug 2014 New trial record
- 29 Apr 2009